Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Small-cell lung cancer].

N Masuda1

  • 1IInd Department of Internal Medicine, Osaka Prefectural Habikino Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 29, 2000
PubMed
Summary
This summary is machine-generated.

Small-cell lung cancer (SCLC) treatment has seen limited progress recently. New agents like irinotecan offer hope for more effective systemic therapies for this aggressive form of lung cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.

ESMO open·2024
Same author

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial.

Breast cancer (Tokyo, Japan)·2018
Same author

Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Area of Science:

  • Oncology
  • Pulmonology
  • Medical Oncology

Background:

  • Small-cell lung cancer (SCLC) accounts for 15-20% of all lung cancer diagnoses.
  • SCLC typically presents as disseminated disease, necessitating systemic treatment approaches.
  • Despite historical advances in chemotherapy and chemoradiotherapy, recent decades show minimal therapeutic progress.

Purpose of the Study:

  • To review current treatment strategies for small-cell lung cancer.
  • To highlight recent advances and emerging agents in SCLC therapy.
  • To discuss the role of radiotherapy, surgery, and prophylactic cranial irradiation.

Main Methods:

  • Literature review of SCLC treatment strategies.
  • Analysis of historical and recent therapeutic advancements.

Related Experiment Videos

  • Evaluation of novel chemotherapeutic agents and supportive care modalities.

    • Main Results:

    • Combination chemotherapy and chemoradiotherapy were significant in the 1970s and 1980s.
    • No major therapeutic breakthroughs have occurred in the last decade.
    • New agents, such as irinotecan, show promise for improved SCLC treatment outcomes.

    Conclusions:

    • Current SCLC treatment relies on systemic therapy due to disease presentation.
    • Limited progress necessitates exploration of novel agents and strategies.
    • Future SCLC therapies may involve new agents combined with established modalities like radiotherapy.